Table Info

Table 3.

Clinical characteristics in different groups

Characteristics	Group 1 (N = 1,601)	Group 2 (N = 92)	Group 3 (N = 826)	Group 4 (N = 137)	P value
CAVI	8.49 ± 1.33	8.20 ± 1.15^*	8.56 ± 1.33^#	8.43 ± 1.18	0.085
Calcium channel blocker (%)	21.55	15.22	26.39	9.49	< 0.001
Angiotensin-converting enzyme inhibitors (%)	3.94	4.35	3.87	4.38	0.988
Angiotensin II receptor blocker (%)	13.30	13.04	17.92	10.95	0.011
Beta blockers (%)	9.93	4.35	12.47	5.84	0.013
Glycosidase inhibitors (%)	8.68	8.70	9.32	8.76	0.964
Metformin (%)	8.12	5.43	9.08	5.84	0.430
Sulfonylureas (%)	3.56	2.17	4.72	2.19	0.287
Insulin (%)	2.56	7.61	3.87	2.92	0.052
Statins (%)	23.30	21.74	27.97	15.33	0.004

Comparisons between multiple groups were used by analysis of variance. Proportions were analyzed by χ²-test. ^* vs Group 1, P < 0.05; ^# vs Group 2, P < 0.05. Group 1: subjects with normal TG and LDL-C; Group 2: subjects with normal TG and hyper-LDL-C; Group 3: subjects with hypertriglyceridemia and normal LDL-C; Group 4: subjects with hypertriglyceridemia and hyper-LDL-C. CAVI: cardio-ankle vascular index

Declarations

Author contributions

JL: Conceptualization, Writing—original draft, Writing—review & editing. HW: Conceptualization, Writing—review & editing. HL, HZ and NZ: Formal analysis, Writing—review & editing. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

No conflicts of interest, financial or otherwise, are declared by all authors.

Ethical approval

This study was approved by the ethics committee of Peking University Shougang Hospital (reference number: SGYYZ202105).

Consent to participate

During the initial visit, the participant was informed that their clinical data might be used for future analysis and publication of academic papers, and the informed consent was obtained from all individual participants included in the study. We are also deeply grateful for the patient’s participation.

Consent to publication

The patients were informed that their clinical data might be used for future analysis and publication of academic papers, and the consent was obtained.

Availability of data and materials

The datasets that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

This work was supported by the Capital’s Funds for Health Improvement and Research [2020-2-6042]; Key medical disciplines/schools of Shijingshan district (Vascular Medicine); Key clinical projects in Peking University Shougang Hospital [2019-Yuan-LC-01]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Cavalcante JL, Lima JAC, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57:1511–22. [DOI] [PubMed]

Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–7. [DOI] [PubMed]

Park SY, Chin SO, Rhee SY, Oh S, Woo JT, Kim SW, et al. Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus. Diabetes Metab J. 2018;42:285–95. [DOI] [PubMed] [PMC]

Sun CK. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integr Blood Press Control. 2013;6:27–38. [DOI] [PubMed] [PMC]

Wang H, Liu J, Wang Q, Zhao H, Shi H, Yu X, et al. Descriptive study of possible link between cardioankle vascular index and homocysteine in vascular-related diseases. BMJ Open. 2013;3:e002483. [DOI] [PubMed] [PMC]

Wang H, Liu J, Zhao H, Zhao X, Li L, Shi H, et al. Relationship between cardio-ankle vascular index and plasma lipids in hypertension subjects. J Hum Hypertens. 2015;29:105–8. [DOI] [PubMed]

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ. Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension. Vasc Health Risk Manag. 2013;9:763–8. [DOI] [PubMed] [PMC]

Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep. 2007;9:139–44. [DOI] [PubMed]

Shirai K, Utino J, Saiki A, Endo K, Ohira M, Nagayama D, et al. Evaluation of blood pressure control using a new arterial stiffness parameter, cardio-ankle vascular index (CAVI). Curr Hypertens Rev. 2013;9:66–75. [DOI] [PubMed] [PMC]

10.

Namba T, Masaki N, Takase B, Adachi T. Arterial Stiffness Assessed by Cardio-Ankle Vascular Index. Int J Mol Sci. 2019;20:3664. [DOI] [PubMed] [PMC]

11.

Niwa H, Takahashi K, Dannoura M, Oomori K, Miyoshi A, Inada T, et al. The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. J Atheroscler Thromb. 2019;26:616–23. [DOI] [PubMed] [PMC]

12.

Lamacchia O, Sorrentino MR, Picca G, Paradiso M, Maiellaro P, Cosmo SD. Cardio-ankle vascular index is associated with diabetic retinopathy in younger than 70 years patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019;155:107793. [DOI] [PubMed]

13.

Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, et al. Cardio-Ankle Vascular Index and C-Reactive Protein Are Useful Parameters for Identification of Ischemic Heart Disease in Acute Heart Failure Patients. J Clin Med Res. 2017;9:439–45. [DOI] [PubMed] [PMC]

14.

Schillaci G, Battista F, Settimi L, Anastasio F, Pucci G. Cardio-ankle vascular index and subclinical heart disease. Hypertens Res. 2015;38:68–73. [DOI] [PubMed]

15.

Wang H, Liu J, Zhao H, Fu X, Shang G, Zhou Y, et al. Arterial stiffness evaluation by cardio-ankle vascular index in hypertension and diabetes mellitus subjects. J Am Soc Hypertens. 2013;7:426–31. [DOI] [PubMed]

16.

Wang H, Liu J, Zhao H, Zhou Y, Zhao X, Song Y, et al. Relationship between cardio-ankle vascular index and N-terminal pro-brain natriuretic peptide in hypertension and coronary heart disease subjects. J Am Soc Hypertens. 2014;8:637–43. [DOI] [PubMed]

17.

Liu J, Liu H, Zhao H, Zhou Y, Li L, Wang H. Relationship between cardio-ankle vascular index and homocysteine in hypertension subjects with hyperhomocysteinemia. Clin Exp Hypertens. 2016;38:652–7. [DOI] [PubMed]

18.

Matsushita K, Ding N, Kim ED, Budoff M, Chirinos JA, Fernhall B, et al. Cardio-ankle vascular index and cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies. J Clin Hypertens (Greenwich). 2019;21:16–24. [DOI] [PubMed] [PMC]

19.

Kamon T, Kaneko H, Itoh H, Kiriyama H, Mizuno Y, Morita H, et al. Gender-specific association between the blood pressure category according to the updated ACC/AHA guidelines for hypertension and cardio-ankle vascular index: a community-based cohort study. J Cardiol. 2020;75:578–82. [DOI] [PubMed]

20.

Du R, Li M, Wang X, Wang S, Li S, Tian H, et al. LDL-C/HDL-C ratio associated with carotid intima-media thickness and carotid plaques in male but not female patients with type 2 diabetes. Clin Chim Acta. 2020;511:215–20. [DOI] [PubMed]

21.

Nagayama D, Watanabe Y, Saiki A, Shirai K, Tatsuno I. Lipid Parameters are Independently Associated with Cardio-Ankle Vascular Index (CAVI) in Healthy Japanese Subjects. J Atheroscler Thromb. 2018;25:621–33. [DOI] [PubMed] [PMC]

22.

Laucevičius A, Ryliškytė L, Balsytė J, Badarienė J, Puronaitė R, Navickas R, et al. Association of cardio-ankle vascular index with cardiovascular risk factors and cardiovascular events in metabolic syndrome patients. Medicina (Kaunas). 2015;51:152–8. [DOI] [PubMed]

23.

Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114:171–82. [DOI] [PubMed]

24.

Satoh-Asahara N, Kotani K, Yamakage H, Yamada T, Araki R, Okajima T, et al.; Japan Obesity and Metabolic Syndrome Study (JOMS) Group. Cardio-ankle vascular index predicts for the incidence of cardiovascular events in obese patients: a multicenter prospective cohort study (Japan Obesity and Metabolic Syndrome Study: JOMS). Atherosclerosis. 2015;242:461–8. [DOI] [PubMed]

25.

Gomez-Sanchez L, Garcia-Ortiz L, Patino-Alonso MC, Recio-Rodriguez JI, Fernando R, Marti R, et al.; MARK Group. Association of metabolic syndrome and its components with arterial stiffness in Caucasian subjects of the MARK study: a cross-sectional trial. Cardiovasc Diabetol. 2016;15:148. [DOI] [PubMed] [PMC]

26.

Gómez-Marcos MÁ, Recio-Rodríguez JI, Patino-Alonso MC, Agudo-Conde C, Gómez-Sánchez L, Gomez-Sanchez M, et al.; LOD-DIABETES Group. Cardio-ankle vascular index is associated with cardiovascular target organ damage and vascularstructure and function in patients with diabetes ormetabolic syndrome, LOD-DIABETES study: a case series report. Cardiovasc Diabetol. 2015;14:7. [DOI] [PubMed] [PMC]

27.

Homma S, Kato K, Hayashi J, Yamamoto M. Negative associations between arterial stiffness parameter evaluated by cardio-ankle vascular index and serum low-density lipoprotein cholesterol concentration in early-stage atherosclerosis. Angiology. 2015;66:143–9. [DOI] [PubMed]

28.

Higashiyama A, Wakabayashi I, Kubota Y, Adachi Y, Hayashibe A, Nishimura K, et al. Does high-sensitivity C-reactive protein or low-density lipoprotein cholesterol show a stronger relationship with the cardio-ankle vascular index in healthy community dwellers?: the KOBE study. J Atheroscler Thromb. 2012;19:1027–34. [DOI] [PubMed]

29.

Xu Y, Yan H, Yao MJ, Ma J, Jia JM, Ruan FX, et al. Cardioankle vascular index evaluations revealed that cotreatment of ARB Antihypertension medication with traditional Chinese medicine improved arterial functionality. J Cardiovasc Pharmacol. 2013;61:355–60. [DOI] [PubMed]

30.

Miyashita Y, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. J Atheroscler Thromb. 2009;16:621–6. [DOI] [PubMed]

31.

Sato S, Takahashi M, Mikamo H, Kawazoe M, Iizuka T, Shimizu K, et al. Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention. Heart Vessels. 2020;35:1664–71. [DOI] [PubMed] [PMC]

32.

Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:539–45. [DOI] [PubMed]

33.

Saiki A, Watanabe Y, Yamaguchi T, Ohira M, Nagayama D, Sato N, et al. CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. J Atheroscler Thromb. 2021;28:1083–94. [DOI] [PubMed] [PMC]

34.

Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract. 2010;64:1796–801. [DOI] [PubMed]

35.

Cozma A, Sitar-Taut A, Orăşan O, Leucuta D, Alexescu T, Stan A, et al. Determining Factors of Arterial Stiffness in Subjects with Metabolic Syndrome. Metab Syndr Relat Disord. 2018;16:490–6. [DOI] [PubMed]

36.

Kawasoe S, Ide K, Usui T, Kubozono T, Yoshifuku S, Miyahara H, et al. Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol. Circ J. 2018;82:3052–7. [DOI] [PubMed]

37.

Zhan B, Huang X, Wang J, Qin X, Zhang J, Cao J, et al. Association Between Lipid Profiles and Arterial Stiffness in Chinese Patients With Hypertension: Insights From the CSPPT. Angiology. 2019;70:515–22. [DOI] [PubMed]

38.

Chotimol P, Saehuan C, Kumphune S. Correlation between cardio-ankle vascular index and biomarkers of oxidative stress. Scand J Clin Lab Invest. 2016;76:105–11. [DOI] [PubMed]

39.

Topouchian J, Labat C, Gautier S, Bäck M, Achimastos A, Blacher J, et al. Effects of metabolic syndrome on arterial function in different age groups: the Advanced Approach to Arterial Stiffness study. J Hypertens. 2018;36:824–33. [DOI] [PubMed] [PMC]